Clinical Trial Update: Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating capecitabine, oxaliplatin, and trastuzumab for HER2-positive metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED